Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Healthlead PCLBKK:HL -4.67%72 5-Year Yield-on-Cost % is 4.07 as of Aug. 21, 2026, which is 144% above its 10-year median of 1.67. GuruFocus rates BKK:HL with a GF Score™ of 72/100 and a GF Value™ of ฿11.00 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 278 Healthcare Providers & Services companies, Healthlead PCL ranks better than 62.95% on this metric.
Healthlead PCL's yield on cost for the quarter that ended in Mar. 2026 was 4.07.
The historical rank and industry rank for Healthlead PCL's 5-Year Yield-on-Cost % or its related term are showing as below:
BKK:HL'
s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.53 Med: 1.67 Max: 4.07
Current: 4.07
During the past 7 years, Healthlead PCL's highest Yield on Cost was 4.07. The lowest was 0.53. And the median was 1.67.
BKK:HL's 5-Year Yield-on-Cost % is ranked better than 62.95% of 278
companies
in the Healthcare Providers & Services industry
Industry Median: 2.91
vs BKK:HL: 4.07
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Healthlead PCL 5-Year Yield-on-Cost % Related Terms
For the Pharmaceutical Retailers subindustry, Healthlead PCL's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Healthlead PCL 5-Year Yield-on-Cost % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Healthlead PCL's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Healthlead PCL's 5-Year Yield-on-Cost % falls into.
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Therefore, Yield-on-Cost of Healthlead PCL is calculated as
Healthlead PCL (BKK:HL) has a 5-Year Yield-on-Cost % of 4.07 as of Aug. 21, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Healthlead PCL and its competitors. This is 144% above median its historical median of 1.67. Over the past decade, Healthlead PCL's 5-Year Yield-on-Cost % has ranged from 0.53 to 4.07. According to the industry distribution chart, Healthlead PCL ranks #103 out of 278 companies in the Healthcare Providers & Services industry, placing it in the top 37.1%.
Is Healthlead PCL's 5-Year Yield-on-Cost % too high?
Healthlead PCL's current 5-Year Yield-on-Cost % of 4.07 is 144% above median its 10-year median of 1.67. Over the past 10 years, this metric has ranged from a low of 0.53 to a high of 4.07. The Healthcare Providers & Services industry median 5-Year Yield-on-Cost % is 2.91. Healthlead PCL's value of 4.07 is 39.9% above this industry median. Based on the distribution chart, Healthlead PCL ranks #103 out of 278 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, Healthlead PCL has a GF Score™ of 72/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Healthlead PCL's 5-Year Yield-on-Cost % compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, Healthlead PCL ranks #103 out of 278 companies for 5-Year Yield-on-Cost %. This puts Healthlead PCL in the upper half of its industry. The industry median 5-Year Yield-on-Cost % is 2.91. Healthlead PCL's value of 4.07 is 39.9% above this benchmark. Historically, Healthlead PCL's own 5-Year Yield-on-Cost % has ranged from 0.53 to 4.07 over the past decade. While the company's 10-year median is 1.67 vs. the industry median of 2.91, Healthlead PCL has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Healthcare Providers & Services company?
The median 5-Year Yield-on-Cost % among Healthcare Providers & Services companies is 2.91, based on 278 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Healthlead PCL's current 5-Year Yield-on-Cost % of 4.07 is 39.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Healthlead PCL and its competitors. For the Healthcare Providers & Services industry, the median 5-Year Yield-on-Cost % is 2.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Healthlead PCL's current 5-Year Yield-on-Cost % is 4.07, which is 144% above median its own 10-year median of 1.67. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Healthlead PCL stock overvalued right now?
Based on GuruFocus' analysis, Healthlead PCL (BKK:HL) is currently considered Significantly Undervalued. The stock's GF Value™ is ฿11.00, compared to a current price of ฿5.10 — trading 53.6% below its estimated fair value. The current 5-Year Yield-on-Cost % is 4.07, which is 144% above median its 10-year median of 1.67 and 39.9% above the Healthcare Providers & Services industry median of 2.91. Healthlead PCL's overall GF Score™ is 72/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Healthlead PCL (BKK:HL), the current 5-Year Yield-on-Cost % is 4.07 as of Aug. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Healthlead PCL (BKK:HL) Overvalued in 2026?
Based on GuruFocus' analysis, Healthlead PCL stock appears to be undervalued.
The current stock price of ฿5.10 is trading 53.6% below its estimated GF Value™ of ฿11.00.
GuruFocus considers Healthlead PCL to be Significantly Undervalued.
Key valuation signals for BKK:HL:
5-Year Yield-on-Cost %: 4.07 (144% above median its 10-year median of 1.67)
GF Value™: ฿11.00 vs. price of ฿5.10 (53.6% below fair value)
Industry Position: 39.9% above the Healthcare Providers & Services median (#103 of 278)
No single metric tells the full story. See the BKK:HL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Healthlead PCL is a holding company. Along with its subsidiaries, it operates a pharmacy business under iCare, Pharmax, vitaminclub, and Super Drug brands, distributing medicines, medical supplies, cosmeceuticals, dietary supplements, medical devices, and other healthcare products. Additionally, it is involved in co-inventing and co-developing healthcare products in collaboration with external research teams and contract manufacturers, producing and distributing its own branded products. Geographically, the group operates only in Thailand.
72GF Score
Get the complete analysis for BKK:HL
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BKK:HL has been successfully added to your 
